+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

L

Actively Recruiting

Researchers are evaluating changes in bone mineral density in premenopausal women with heavy menstrual bleeding caused by uterine fibroids or moderate-to-severe pain from endometriosis. This Phase 3B, open-label study looks at the effects of continuous treatment with a relugolix combination tablet for up to 48 months 4 years, followed by a 1-year period to monitor bone health after stopping treatment. Participants will take a daily oral relugolix combination tablet containing relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg for 4 years. Bone mineral density will be measured every 6 months using dual-energy X-ray absorptiometry DXA. Some women who have completed a previous related study may join to complete 3 years of treatment. After treatment ends, bone density will be checked again at 6 months and 12 months during the follow-up year. Women in the study will have regular visits for bone density scans and health assessments, including physical and gynecological exams, lab tests, and vital signs. Researchers will track changes in bone density at the spine, hip, and femoral neck throughout treatment and follow-up. They will also monitor for any fractures or adverse events during the 4 years of treatment and the 1-year post-treatment period. Total participation can last up to 5 years including the follow-up.

Age: 18Years - 50YearsFEMALEPhase 3
120 locations
T

Actively Recruiting

This research aims to understand the relationship between donor-derived cell-free DNA DD-cfDNA levels and HLA antibodies in blood samples from heart transplant recipients. It compares these blood test results with the Molecular Microscope Diagnostic System MMDx, a new diagnostic method that uses gene expression microarrays to assess heart transplant rejection and injury. The study focuses on improving the accuracy of rejection assessment beyond the current standard biopsy method, which has limitations due to variability in pathologist interpretations. Participants include heart transplant patients undergoing biopsies either for clinical reasons or as part of routine protocol monitoring. The study collects and compares data from 300 biopsies and 600 blood samples, using the Prospera test to measure DD-cfDNA levels and the MMDx system to analyze biopsy gene expression profiles. It also includes centralized testing of HLA antibodies in blood to assess donor-specific antibody status. Participants will be monitored through their standard care biopsies and blood sample collections. Researchers will evaluate the calibration of the Prospera test against MMDx findings for T cell-mediated rejection, antibody-mediated rejection, and heart injury over 18 months. Outcomes include reporting calibrated test results and assessing whether the Prospera blood test could potentially replace biopsy tests for rejection and follow-up. The study is ongoing until July 2028, with safety and diagnostic accuracy as key assessments.

All AgesAll Genders
12 locations